Veil Therapeutics
- Biotech or pharma, therapeutic R&D

Veil Therapeutics is developing VTX-101, a polymer-conjugated enzyme, for the treatment of chronic refractory gout. This preclinical program is enabled by Veil's proprietary stealth polymer platform which retains the PK/PD and stability benefits of PEGylation with a significantly reduced immunogenicity profile. Veil's internal pipeline is focused on protein - polymer conjugates and is looking for partnerships around novel peptide, lipid nanoparticle (LNP), and RNA aptamer - polymer conjugates.
Address
DurhamNorth Carolina
United States